Page last updated: 2024-12-06

nitrosocimetidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitrosocimetidine: possible metabolite of cimetidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID52445
MeSH IDM0072002

Synonyms (10)

Synonym
73785-40-7
2-cyano-1-methyl-3-(2-{[(4-methyl-1h-imidazol-5-yl)methyl]thio}ethyl)-1-nitrosoguanidine
n-nitrosocimetidine
nitrocimetidine
nitrosocimetidine
ccris 1952
guanidine, n'-cyano-n-methyl-n''-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-n-nitroso-
guanidine, 2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)-1-nitroso-
3-cyano-1-methyl-2-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-1-nitrosoguanidine
DTXSID7021025

Research Excerpts

Overview

N-Nitrosocimetidine (NCM) is a derivative of the drug cimetidine, a methylguanidine derivative used in the treatment of peptic ulcer. It is known to be inactive as a complete mouse skin carcinogen.

ExcerptReferenceRelevance
"N-Nitrosocimetidine (NCM) is a derivative of the drug cimetidine, a methylguanidine derivative used in the treatment of peptic ulcer, and is known to be inactive as a complete mouse skin carcinogen, even when given in repeated high doses for a long period. "( N-nitrosocimetidine as an initiator of murine skin tumors with associated H-ras oncogene activation.
Anderson, LM; Enomoto, T; Giner-Sorolla, A; Kovatch, RM; Perantoni, AO; Reed, CD; Rice, JM; Riggs, CW, 1989
)
1.72
"N-Nitrosocimetidine (NCM) is a nitrosation product of cimetidine, a commonly-prescribed pharmaceutical agent. "( N-nitrosocimetidine as a modifier of chemically-initiated tumors in mice.
Anderson, LM; Giner-Sorolla, A; Hagiwara, A; Kovatch, RM; Rehm, S; Rice, JM; Riggs, CW, 1988
)
1.72

Toxicity

ExcerptReferenceRelevance
" According to median lethalities, all three known carcinogens were substantially more toxic than nitrosocimetidine whether administered by the intravenous, intraperitoneal, or oral routes."( Comparison of the acute toxicity of N-nitrosocimetidine with three structurally related carcinogens in the rat.
Hard, GC; Jensen, DE; Magee, PN; Ogiu, T, 1986
)
0.76

Dosage Studied

ExcerptRelevanceReference
" and the circulating blood levels of intact and denitrosated compound 5 min after dosing quantified."( Evidence for cytosolic glutathione transferase-mediated denitrosation of nitrosocimetidine and 1-methyl-2-nitro-1-nitrosoguanidine.
Jensen, DE; Stelman, GJ, 1987
)
0.5
" For comparison, the DNA methylation produced by the carcinogen N-methyl-N-nitro-N-nitrosoguanidine (MNNG) dosed orally was measured."( DNA-methylation by nitrosocimetidine and N-methyl-N-nitro-N-nitrosoguanidine in the intact rat.
Gombar, CT; Magee, PN, 1982
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (84.38)18.7374
1990's4 (12.50)18.2507
2000's1 (3.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.42 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index3.98 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]